Ik Sung Kwon, MD
Retina Specialist · Warsaw, NYNPI 1366468035
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Genentech USA, Inc. at 30.3% of the total. That places this record below the midpoint for retina specialist clinicians in NY, where the typical reported total is $2,298.
Across 17 payments — averaging $22.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$116
- Regeneron Healthcare Solutions, Inc.$94
- Astellas Pharma US Inc$88
- Apellis Pharmaceuticals, Inc.$54
- Harrow Eye, LLC$30
What the payments were for
- Food & beverage$381100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 5 | $116 |
| Regeneron Healthcare Solutions, Inc. | 4 | $94 |
| Astellas Pharma US Inc | 4 | $88 |
| Apellis Pharmaceuticals, Inc. | 3 | $54 |
| Harrow Eye, LLC | 1 | $30 |
How this compares
$381 in reported general payments places this provider in the 15th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ofloxacin | 974 | $12,341 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 39 | $6,520 |
| MoxifloxacinMoxifloxacin Hcl | 215 | $6,290 |
| Prednisolone Acetate | 120 | $4,336 |
| Brimonidine Tartrate | 232 | $3,765 |
| Latanoprost | 228 | $2,523 |
| Timolol Maleate | 172 | $1,765 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 35 | $1,696 |
| Dorzolamide Hcl | 56 | $939 |
| Ketorolac Tromethamine | 21 | $543 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 29 | $497 |
| Ciprofloxacin Hcl | 24 | $280 |
| Gentamicin Sulfate | 23 | $220 |
| Levobunolol Hcl | 12 | $203 |
| Ondansetron Hcl | 48 | $141 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Warsaw
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
- Donald D'amicoNew York$109K
- Matthew WitmerRochester$62K
- Avnish DeobhaktaBrooklyn$46K
- Edward HallRochester$38K
- Philip NilesWilliamsville$30K
- Mark BreazzanoLiverpool$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.